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Background: This article evaluates the accuracy of family history of breast and ovarian cancer among first-
degree relatives of breast cancer patients, retrospectively collected during the setting up of a population-based
family breast cancer registry.
Patients and methods: Family histories of cancer for all women with breast cancer recorded at the Geneva
Cancer Registry from 1990 to 1999 were retrospectively extracted from medical files. The accuracy of these
family histories was validated among Swiss women born in Geneva: all 119 with a family history of breast
(n = 110) or ovarian (n = 9) cancer and a representative sample of 100 women with no family history of breast or
ovarian cancer. We identified the first-degree relatives of these women with information from the Cantonal
Population Office. All first-degree relatives, resident in Geneva from 1970 to 1999, were linked to the cancer
registry database for breast and ovarian cancer occurrence. Sensitivity, specificity and level of overall agree-
ment (κ) were calculated.
Results: Among 310 first-degree relatives identified, 61 had breast cancer and six had ovarian cancer recorded
at the Geneva Cancer Registry. The sensitivity, specificity and κ of the reported family histories of breast cancer
were 98%, 97% and 0.97, respectively. For ovarian cancer, the sensitivity, specificity and κ were 67%, 99%,
and 0.66, respectively.
Conclusions: This study indicates that retrospectively obtained family histories are very accurate for breast
cancer. For ovarian cancer, family histories are less precise and may need additional verification.
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Introduction
Breast cancer is the most common malignancy among women in
industrialised countries and the Swiss canton of Geneva presents
one of the highest incidence rates worldwide [1]. A family history
of breast and/or ovarian cancer is one of the strongest known risk
factors for breast cancer [2]. Several epidemiological studies have
demonstrated that female relatives of breast cancer patients are at
increased risk of developing breast cancer and that the extent of
this risk varies according to the degree of the genetic relationship
with the affected relative, age at onset of breast cancer in the
relative and total number of affected relatives [3–6]. Family
history of breast cancer is an important parameter in statistical
models, developed to determine cumulative breast cancer risk
[7, 8] or to evaluate the probability of carrying a genetic predis-
position for breast or ovarian cancer [9]. Two major dominantly
inherited genes predisposing to breast and ovarian cancer have
been identified, BRCA1 and BRCA2. These germ-line mutations
account for 5–10% of all breast and ovarian cancers [10]. There-
fore, a large proportion of the familial clustering of breast
and ovarian cancer remains unexplained. Particular clinico-
pathological characteristics and differences in outcome have been
reported for cases of breast cancer developing in familial clusters
compared to sporadic cases [11].
Innumerable research groups all over the world work to unravel
the complex relation between family history of breast cancer and
increased risk of developing the disease. Population-based famil-
ial cancer registries are of great value in assessing the importance
of family history on breast cancer risk in a defined population and
permit epidemiological research on etiology, clinico-pathological
characteristics, management and outcome of women with familial
breast cancer. However, the number of population-based cancer
registries is relatively low [12, 13].
In the Swiss canton of Geneva a population-based familial
breast cancer registry has recently been established [14]. This
registry includes all women diagnosed with breast cancer in the
canton since 1990. For cases diagnosed from 1990 to 1999, family
history was retrospectively retrieved using information from
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hospital files and files of private physicians. A few studies have
assessed the accuracy of reported family history. Most of these
studies involved selected patients referred to genetic counselling
units [15–18] or included in a case–control study [19]. To our
knowledge, only one population-based breast cancer registry was
validated by comparing the information in the familial cancer
registry database with that obtained by personal interviews [20].
In this study, we present the results of the validation of reported
family histories of breast and ovarian cancer among first-degree
relatives in the Geneva population-based familial breast cancer
registry.
Patients and methods
The Geneva Familial Breast Cancer Registry was created in the framework of
the Geneva Cancer Registry. Briefly, the Geneva Cancer Registry records all
incident cancers occurring in the population of the canton (~420 000 inhabit-
ants) since 1970. It collects information from various sources, and is consid-
ered accurate, as attested by its very low percentage (<2%) of cases recorded
from death certificates only [21]. All hospitals, pathology laboratories and
private practitioners in the canton are requested to report all cancer cases.
Trained tumor registrars systematically abstract data from medical and labora-
tory records. Physicians regularly receive inquiry forms to secure missing clin-
ical and therapeutic data. Death certificates are consulted systematically.
Recorded data include socio-demographic information, method of discovery,
type of confirmation, tumor characteristics (coded according to the Inter-
national Classification of Diseases for Oncology) [22], stage of disease at
diagnosis, hormonal receptor status, treatment during the first 6 months after
diagnosis, survival status and cause of death.
The Geneva Familial Breast Cancer Registry includes all women diagnosed
with breast cancer in the Geneva population since 1990. For the women diag-
nosed from 1990 to 1999, we retrospectively collected information on family
history of cancer according to a standard questionnaire, using information
from medical records from the public university hospital and private physi-
cians. The retrospectively retrieved information on family history of breast
and ovarian cancer among first-degree relatives was validated. This validation
study comprised all Swiss breast cancer patients born in Geneva who had at
least one relative with breast cancer (n = 110) or ovarian cancer (n = 9), and a
random sample of 100 Swiss patients, born in Geneva, who had no family his-
tory of breast or ovarian cancer. For each of those 219 patients, we identified
all female first-degree relatives with information from the Cantonal Popu-
lation Office. This institution is in charge of the registration of socio-
demographic information of actual and previous inhabitants of the Geneva
canton. All first-degree relatives, who were resident in the canton from 1970
(the start of the Geneva cancer registry) to 1999, were then linked to the
Geneva Cancer Registry database. Thus, all first-degree relatives diagnosed
with breast or ovarian cancer were ascertained.
By comparing the retrospectively obtained family histories with the com-
bined information of the Cantonal Population Office and the Geneva Cancer
Registry, we calculated sensitivity, specificity and predictive values of the
reported family histories using standard statistic procedures. The information
obtained from the Cantonal Population Office in combination with the Geneva
Cancer Registry was taken as reference standard. Level of agreement between
reported and validated familial breast cancer histories, corrected for the agree-
ment due to chance only, was evaluated using the κ statistic [23].
Results
From 1990 to 1999, 2957 women were diagnosed with invasive
breast cancer in the canton of Geneva. We found information on
family history of breast cancer for 2648 (90%) of these women. A
total of 433 (16%) women were of Swiss nationality and born in
Geneva: 110 (25%) reported a family history of breast cancer,
nine (0.6%) a family history of ovarian cancer.
For the 119 women with a family history and the random
sample of 100 women without a family history included in the
validation set, we identified 310 first-degree relatives, who were
resident in Geneva from 1970 to 1999 (109 mothers, 75 identified
sisters and 134 daughters).
After linkage of these first-degree relatives with the Geneva
Cancer Registry database, 61 appeared to have been diagnosed
with breast cancer and six with ovarian cancer.
The results of the validation of the reported family history of
breast cancer among first-degree relatives is presented in Table 1.
The accuracy of the reported family history on breast cancer was
high. Only two mothers were incorrectly reported as having had
breast cancer (false positives): one mother was diagnosed with
bladder cancer and the other one was never diagnosed with cancer.
For one mother, no history of breast cancer was reported, while in
fact she had been diagnosed with breast cancer (false negative).
The accuracy of the reported history of breast cancer for sisters
and daughters was also very high. Taking all first-degree relatives
(mothers, sisters and daughters) together, the sensitivity, speci-
ficity, positive and negative predictive values of the reported
family history of breast cancer were 98%, 97%, 97% and 100%,
respectively. The overall level of concordance between the
reported family history of breast cancer and the family history
according to the combined information of the Cantonal Popula-
Table 1. Validation of reported history of breast cancer among first-degree relatives of 219 women diagnosed with breast cancer
aAs reported in the medical records.
BC+, presence of breast cancer; BC–, absence of breast cancer; FDR, first-degree relative.
n Positive 
family historya
Negative 
family historya
Sensitivity,
%
Specificity,
%
Predictive value, %
BC+ BC– BC+ BC– Positive Negative
Mothers 109 39 2 1 67 98 97 95 99
Sisters 67 18 0 0 49 100 100 100 100
Daughters 134 3 0 0 131 100 100 100 100
All FDRs 310 60 2 1 247 98 97 97 100
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tion Office and the Geneva Cancer Registry was very high
[κ score, 0.97; 95% confidence interval (CI) 0.94–1.0] [23].
For ovarian cancer, the reported family history among first-
degree relatives was less accurate (Table 2). Five women reported
ovarian cancer in their mothers, but in two cases, this was errone-
ous, as both mothers were in fact diagnosed with endometrial
cancer (false positives). One mother and one sister were incor-
rectly not reported to have had ovarian cancer (false negatives).
Taking mothers and sisters together (daughters were excluded
from this analysis, because there were no daughters reported to
have had ovarian cancer and we did not identify any daughters
with ovarian cancer during validation), the sensitivity, specificity,
positive and negative predictive values of the reported family
history of ovarian cancer were 67%, 99%, 67% and 99%, respect-
ively. The overall level of concordance between the reported
family history of ovarian cancer in mothers and sisters and the
family history according to the combined information of the OCP
(Cantonal Population Office) and the Geneva cancer registry was
substantially lower than that for breast cancer. The κ score was
0.66 (95% CI 0.34–0.97) indicating an ‘acceptable’ agreement
[23].
Discussion
This study has indicated that the retrospectively obtained family
histories of the Geneva Familial Breast Cancer Registry are very
accurate for breast cancer, whereas for ovarian cancer they are less
accurate, but because a comparably low validity of reported
family histories of ovarian cancer has also been reported in
prospective validation studies [17, 19], it is probably not due to the
retrospective nature of the data collection. Lack of knowledge and
clarity on ovarian cancer are likely to hamper accurate reporting
of ovarian cancer among family members.
Anton-Culver et al. [20] have validated the family histories of
breast cancer among mothers and sisters of breast cancer patients.
Family history was obtained in a similar manner as ours i.e. in the
context of a population-based cancer registry using information
from medical records. They used personal interviews to ascertain
the collected family histories of cancer. Sensitivity and specificity
for a family history of breast cancer among 216 mothers were high
(92% and 99%, respectively) and comparable to the results of our
study. For 177 sisters, the sensitivity was somewhat lower (88%)
and the specificity was comparable (99%). Douglas et al. [16]
studied the accuracy of family history of breast cancer, reported
by affected and non-affected female visitors of a genetics depart-
ment. The reported family histories of breast cancer were verified
using death certificates, medical notes, histopathology reports and
cancer registry data. Around 95% of the reported breast cancer
cases among family members were accurate, while for ovarian
cancer 83% of the reported cases were confirmed. In a large case–
control study, validation of family histories of cancer has demon-
strated important differences in sensitivity and overall agreement
for reported family history of breast cancer (83%; κ, 0.63) com-
pared to family history of ovarian cancer (60%; κ, 0.36) [19].
Reasons for false-positive family histories (i.e. specific cancer
in relative reported by proband, while in fact this person was never
diagnosed with this particular cancer) are diverse. In a small
proportion of erroneous family histories, benign diseases are
mistakenly reported as cancer, but more often it is the primary site
that is incorrect [16]. For all cancers, the primary cancer site is
correctly identified in around 64–86% of cases [18]. Our data are
in concordance with these findings: in our series, one of the two
false-positive family breast cancer cases was in fact bladder
cancer, while the other one was no cancer at all. Both falsely
reported family histories of ovarian cancer were in fact uterine
cancer cases. Fictitious family histories of cancer also occur, and
there have even been some rare reports of intentionally fabricated
untrue family histories [16, 24].
There are several shortcomings in our study. First, we limited
our study to first-degree relatives of breast cancer patients.
Because of the methodological approach we choose, identifica-
tion of second- and third-degree relatives of the breast cancer
patients in the cohort would have been too complicated and
inaccurate, as the information on second- and third-degree rela-
tives at the Cantonal Population Office is far less complete and
more difficult to extract. Nevertheless, occurrence of breast or
ovarian cancer in second- or third-degree relatives is also associ-
ated with individual breast cancer risk and accurate reporting is
therefore also very important for these relatives. This is of particu-
lar relevance in genetic counselling, in case of small pedigrees and
breast cancer occurrence in the paternal side of the family. We
know from previous studies that the accuracy of history of breast
and ovarian among second- and third-degree relatives is generally
less accurate than for first-degree relatives. Eerola et al. [15]
reported a sensitivity of breast or ovarian cancer history among
first and second-degree relatives of 100% and 99%, respectively,
but this dropped to 61% for third-degree relatives. Similarly, in
another study, the percentage of accurately reported breast cancer
Table 2. Validation of reported history of ovarian cancer among first-degree relatives of 219 women diagnosed with breast cancer
aAs reported in the medical records.
OC+, presence of ovarian cancer; OC–, absence of ovarian cancer; FDR, first-degree relative.
n Positive family 
historya
Negative family 
historya
Sensitivity, 
%
Specificity, 
%
Predictive value, %
OC+ OC– OC+ OC– Positive Negative
Mothers 109 3 2 1 103 75 98 60 99
Sisters 67 1 0 1 65 50 100 100 98
All FDRs 176 4 2 2 168 67 99 67 99
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histories was 94% for first-degree relatives, 90% for second-
degree relatives and 75% for third-degree relatives [17].
A second shortcoming of our study was that we were only able
to validate the family history of relatives that were resident in
Geneva from 1970 to 1999, because only these women were
covered by the Geneva Cancer Registry. One could postulate that
reported family history for these women is more accurate than for
relatives who have deceased before 1970 or who live abroad,
which is not uncommon in the cosmopolitan population of
Geneva where 30–40% of the population are foreigners. Never-
theless, we accepted this loss of generalisability in order to gain in
the accuracy of the data. Where other studies used personal inter-
views to confirm family history of cancer, leaving room for recall
bias, intentional fictitious family history, unintentional errors,
etc., we are confident that the results we have obtained are very
accurate.
In conclusion, this study has demonstrated that it is possible to
obtain a reliable family history of breast cancer in first-degree
relatives by systematic, retrospective consultation of medical
records. However, our study confirmed that reported family
history for ovarian cancer was less accurate. Therefore, familial
patterns of ovarian cancer require additional verification, particu-
larly when this information is used for cancer risk assessment and
discussions on screening procedures and preventive options.
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